Ventfort
Key Facts: Ventfort
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Duration
- 10-30 day cycles
Mechanism of Action
The proposed idea, like the rest of the Khavinson bioregulators, is that short tissue-derived peptides act selectively on the cells of one organ system - here the vascular wall - entering cells and binding DNA to restore a more normal pattern of gene expression in endothelial and smooth muscle cells. Vendors describe this as 'reminding' blood vessel cells how to function and normalizing vascular metabolism. This selective organ-targeting, gene-regulating mechanism is a hypothesis from Khavinson's group rather than an independently confirmed pathway. No specific receptor, binding affinity, or signaling cascade has been characterized for Ventfort the way it has for an approved vascular drug.
Research Summary
Ventfort sits inside a peptide program with a large Russian publication record and some peer-reviewed mechanistic reviews, but as a named product its evidence base is thin. There are no registered, randomized, placebo-controlled clinical trials of Ventfort in humans for vascular disease, and the supporting work clusters within one research group with little outside replication - the classic signal that results should be treated as preliminary, not confirmatory. The closest relevant science is on the synthetic vascular tripeptide KED (Vesugen), which has been studied for endothelial gene expression effects in cell and animal models, but KED is a defined molecule and Ventfort is a crude tissue extract, so they are not interchangeable. Broader Khavinson reviews report geroprotective and tissue-restorative effects in rodents, yet extrapolating that to a calf-vessel capsule preventing or treating human cardiovascular conditions is unsupported. Anyone with real vascular disease should rely on tested therapy. Honest bottom line: low-quality, single-source evidence and no clinical proof for the specific product.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Vascular bioregulator for blood vessel health. Part of Khavinson system.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Limited safety data outside Russia
- ●Not FDA approved
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9032300/
- https://pubmed.ncbi.nlm.nih.gov/22708439/
- https://link.springer.com/article/10.1134/S2079057012040091
Research This Peptide Further
Frequently Asked Questions
What does Ventfort do?
Ventfort is a Khavinson-line 'cytomax' supplement made from a peptide complex extracted from calf blood vessel tissue, sold under the code A-3 and marketed for vascular and circulatory support. It has no published amino acid sequence, no FDA approval, and no independent randomized human trials. The benefit claims are vendor claims, not established medicine.
How does Ventfort work?
The proposed idea, like the rest of the Khavinson bioregulators, is that short tissue-derived peptides act selectively on the cells of one organ system - here the vascular wall - entering cells and binding DNA to restore a more normal pattern of gene expression in endothelial and smooth muscle cells. Vendors describe this as 'reminding' blood vessel cells how to function and normalizing vascular metabolism. This selective organ-targeting, gene-regulating mechanism is a hypothesis from Khavinson's group rather than an independently confirmed pathway. No specific receptor, binding affinity, or signaling cascade has been characterized for Ventfort the way it has for an approved vascular drug.
Is Ventfort FDA approved?
No, Ventfort is not currently FDA approved. Current status: Preclinical research, approved in Russia as supplement
What are the side effects of Ventfort?
Reported side effects include: Generally well-tolerated, Limited safety data outside Russia, Not FDA approved. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Ventfort?
Community-reported common dose: 10-20 mg daily (Once or twice daily). Range: 10-20 mg daily. Administration: Oral capsules or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Ventfort or used in similar applications.
Livagen
PreclinicalLivagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.
BioregulatorsOvagen
PreclinicalOvagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.
BioregulatorsCortagen
PreclinicalCortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.
BioregulatorsVesugen
PreclinicalVesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson family of short peptide bioregulators, studied for vascular and neuroprotective effects. It is a research compound, not an approved drug, with no registered human clinical trials.
BioregulatorsChonluten
PreclinicalChonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.
BioregulatorsCrystagen
PreclinicalCrystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).
BioregulatorsWant updates on Ventfort research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.